July 24, 2019
Synthorx (NASDAQ:THOR) has announced it has begun its Phase 1/2 clinical trial of THOR-707 in Australia as well as receiving...
December 31, 2018
December brought four life science IPOs on the NASDAQ, giving investors new opportunities to enter the market.
December 16, 2018
Innovate Biopharmaceuticals, Aridis Pharmaceuticals, Imprimis Pharmaceuticals, Achaogen and SynthoRx were last week's top gainers.
December 13, 2018
Synthorx (Nasdaq:THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for...